"Emma Guttman-Yassky Discusses the Role of the Immune Pathway in Atopic Dermatitis"
For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-drive disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, a professor of dermatology at the Icahn School of Medicine at Mount Sinai. “There was not a clear-cut answer because the only way to prove it is actually to target specifics to the immune system and to show that you reversed the barrier. And that was not possible really until dupilumab,” she said. Learn more.
